Company intelligence / Profile preview

Real And Best

Chengdu, Sichuan Province, Chinawatchesofespionage.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Real And Best is a leading Chinese biotech company specializing in rAAV-based gene therapies. Its lead product ZS801 is the first approved gene therapy targeting Hemophilia B to enter clinical trials in China. The company holds world-leading patents for efficient gene expression cassette design and vector production optimization. Research on safety and efficacy of its lead asset is ongoing at the Chinese Academy of Medical Sciences.[1][2][3]

Therapeutic areas: OtherHematology
Modalities: Recombinant adeno-associated virus (rAAV) gene therapy[1][2][3]
Industry: Biotech

Drug pipeline

1 asset

FL115

Pre-clinical

Indications: Cancer

Partnerships

SDIC Venture Capital (lead investor)[1]PanLin Capital[2]Anxin Guosheng Weixin Fund[1]Loyal Valley Capital[1]

Beyond the preview

Go deeper on Real And Best.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Real And Best.

Explore the full profile